• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Apr 14;13:853682.
doi: 10.3389/fimmu.2022.853682. eCollection 2022.
Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients


Lucrezia Furian[SUP] 1 [/SUP], Francesco Paolo Russo[SUP] 2 [/SUP], Gianluigi Zaza[SUP] 3 [/SUP], Patrizia Burra[SUP] 2 [/SUP], Susan Hartzell[SUP] 4 [/SUP], Debora Bizzaro[SUP] 2 [/SUP], Marianna Di Bello[SUP] 1 [/SUP], Caterina Di Bella[SUP] 1 [/SUP], Erica Nuzzolese[SUP] 1 [/SUP], Clara Agnolon[SUP] 2 [/SUP], Sander Florman[SUP] 5 [/SUP], Meenakshi Rana[SUP] 6 [/SUP], Jar-How Lee[SUP] 7 [/SUP], Yesl Kim[SUP] 8 [/SUP], Umberto Maggiore[SUP] 9 [/SUP], Jonathan S Maltzman[SUP] 10 11 [/SUP], Paolo Cravedi[SUP] 4 [/SUP]



Affiliations

Abstract

The antibody and T cell responses after SARS-CoV-2 vaccination have not been formally compared between kidney and liver transplant recipients. Using a multiplex assay, we measured IgG levels against 4 epitopes of SARS-CoV-2 spike protein and nucleocapsid (NC) antigen, SARS-CoV-2 variants, and common coronaviruses in serial blood samples from 52 kidney and 50 liver transplant recipients undergoing mRNA SARS-CoV-2 vaccination. We quantified IFN-γ/IL-2 T cells reactive against SARS-CoV-2 spike protein by FluoroSpot. We used multivariable generalized linear models to adjust for the differences in immunosuppression between groups. In liver transplant recipients, IgG levels against every SARS-CoV-2 spike epitope increased significantly more than in kidney transplant recipients (MFI: 19,617 vs 6,056; P<0.001), a difference that remained significant after adjustments. Vaccine did not affect IgG levels against NC nor common coronaviruses. Elicited antibodies recognized all variants tested but at significantly lower strength than the original Wuhan strain. Anti-spike IFN-γ-producing T cells increased significantly more in liver than in kidney transplant recipients (IFN-γ-producing T cells 28 vs 11 spots/5x10[SUP]5[/SUP] cells), but this difference lost statistical significance after adjustments. SARS-CoV-2 vaccine elicits a stronger antibody response in liver than in kidney transplant recipients, a phenomenon that is not entirely explained by the different immunosuppression.

Keywords: COVID-19; T cell; antibody; immunosuppression; variant.
 
Back
Top Bottom